BIO..."Germany has been known to offer 50% or less".... Germany has a choice...They can choose to allow their patients to suffer a increased rate of CVD or pay what other EU countries have determined is a fair price for Vaskepa...Amarin has NO choice...They could not survive as a going concern with a 50% reduction in their price.
The UK should have already set an EU price - didn't they settle on $180/mo or something? Look at CaptBeers net sales numbers in the US over the last 4-5 yrs:
AMRN went from making ~ $135/monthly scrip down to $100 starting in 2022 - I don't know what "Amarin begins exclusivity contracts" means, but it chopped 26%/script of net revs from AMRN's US sales, and they lost money in Q1/Q2 - clearly that's not enough to support the company. They've never had a profitable quarter in their existence due to non-cash exec comps (~ $80M/yr on free stock to execs and the BOD annually), most they ever made not counting that expense was a few cents - if they were losing money at $135/script, they'll go BK at $100/mo.
Germany asking for 50% off from what the UK is willing to pay, or whatever number AMRN started at ($250?) is not going to happen - AMRN can't sell V at a loss just to sell more volume. This is another case of horrible timing for AMRN - the cost of coal and NG Germany is paying has skyrocketed because of the Russia/Ukraine crisis, and their new austerity plan was in motion even before that happened. Their new proposal to cut orphan drug spending from $50M/yr to $20M/yr per drug is hard to believe - that plus their refusal to agree to a reasonable price for V shows they don't give a damn about helping the unhealthy part of their population, almost like survival of the fittest is the new manta.
News 
Market Data 
Discover 
